FDA Rejects Grace Therapeutics' Stroke Drug on Mfg Concerns

FDA Declines Grace Therapeutics' Stroke Drug

The U.S. Food and Drug Administration (FDA) has declined to approve a new drug from Grace Therapeutics intended for a rare type of stroke. In a complete response letter, the agency cited significant deficiencies related to chemistry, manufacturing, and controls (CMC), rather than issues with the drug's clinical trial data.

Manufacturing and Packaging Concerns Cited

The FDA's decision detailed several key issues that prevented approval. Concerns included inadequate data on 'leachables,' which are chemical compounds that can migrate from product packaging into the drug itself. The agency also noted problems with non-clinical product toxicology risk assessments and specific manufacturing deficiencies at a contract manufacturing facility.

Impact and Company Response

In response to the letter, Grace Therapeutics stated that it believes the issues raised by the FDA are addressable. The company plans to work on resolving the deficiencies for a future resubmission. This regulatory setback will inevitably delay the drug’s potential market entry, a key milestone for the company and a point of focus for its stakeholders.

Conclusion and Outlook

The FDA's rejection underscores the stringent standards for drug manufacturing, packaging, and safety that must be met for approval. The future of Grace Therapeutics' stroke drug now hinges on the company's ability to successfully rectify the specific manufacturing and non-clinical issues identified by the regulators in its next application.

FAQ

Q: Why did the FDA reject Grace Therapeutics' stroke drug?
A: The rejection was due to deficiencies in chemistry, manufacturing, and controls, including issues with packaging leachables and problems at a contract manufacturer.

Q: What is Grace Therapeutics' next step?
A: The company plans to address the specific issues outlined by the FDA and resubmit its application for approval.

Source: Reuters via Investing.com